Matinas BioPharma (NYSE: MTNB) announced on Friday that it received a formal notice from NYSE American on April 2, 2026, indicating non-compliance with the exchange’s listing standards. The notice specifically cited a failure to meet the stockholders’ equity requirements as stipulated under Section 1003(a)(i) of the NYSE American Company Guide.
The communication from NYSE American highlighted that Matinas BioPharma did not satisfy the minimum stockholders’ equity mandates outlined in Sections 1003(a)(i)-(iii). These particular sections are fundamental components of the exchange’s rules, which are designed to ensure that publicly traded companies maintain a certain level of financial health and provide adequate protection for investors. Non-compliance with these equity requirements signals a significant concern regarding the company’s financial standing.
Receiving such a notice initiates a formal process where the company is typically required to address the identified deficiencies. While the immediate implications or Matinas BioPharma’s specific plan to regain compliance were not detailed in the announcement, these notices underscore the exchange’s commitment to upholding its listing criteria. The situation places Matinas BioPharma under scrutiny regarding its ability to meet ongoing financial benchmarks set by the NYSE American.
